Adjunct Fenofibrate Up‐regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis

Gina M. Gallucci, Jocelyn Trottier, Christopher Hemme, David N. Assis, James L. Boyer, Olivier Barbier, Nisanne S. Ghonem – 26 August 2021 – Accumulation of cytotoxic bile acids (BAs) during cholestasis can result in liver failure. Glucuronidation, a phase II metabolism pathway responsible for BA detoxification, is regulated by peroxisome proliferator–activated receptor alpha (PPARα). This study investigates the efficacy of adjunct fenofibrate therapy to up‐regulate BA‐glucuronidation and reduce serum BA toxicity during cholestasis.

Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases

Adriana Psaraki, Lydia Ntari, Christos Karakostas, Despoina Korrou‐Karava, Maria G. Roubelakis – 26 August 2021 – Liver dysfunctions are classified into acute and chronic diseases, which comprise a heterogeneous group of pathological features and a high mortality rate. Liver transplantation remains the gold‐standard therapy for most liver diseases, with concomitant limitations related to donor organ shortage and lifelong immunosuppressive therapy.

S‐adenosylmethionine inhibits la ribonucleoprotein domain family member 1 in murine liver and human liver cancer cells

Komal Ramani, Aaron E. Robinson, Joshua Berlind, Wei Fan, Aushinie Abeynayake, Aleksandra Binek, Lucía Barbier‐Torres, Mazen Noureddin, Nicholas N. Nissen, Zehra Yildirim, Ebru Erbay, José M. Mato, Jennifer E. Van Eyk, Shelly C. Lu – 26 August 2021

Subscribe to